After the last two previous meetings of our Ethics Advisory Board (EAB) -which resulted in reports D2.2 and D2.4-, the EAB members were presented with the updated position with regards to the project objectives and progress, the data protection and ethics oversight and assessments for the project. In this period, GenoMed4All focused its efforts on the finalisation of the Joint Controller Agreements (JCAs), enhancement of the Federated Learning architecture and development of the recommendations on the ethical principles, quality processes and stakeholder engagements for AI development as can be found in deliverable D2.5.
Abstract
Deliverable 2.6 provides the third report of the Ethical Advisory Board for GenoMed4All. The 3rd Meeting took place on Monday 20th November 2023 and provided an opportunity for the project to update the EAB external members on the latest developments over 2023. The key points of development included the completion and signing and execution of three Joint Controller Agreements for each of the Use Cases, further technical developments that place the majority of personal data processing on a Federated Learning infrastructure and finalisation of the approach to develop the Ethical Principles and Quality Assurances for Deliverable 2.5. There was also reflection on the recently enacted Data Governance Act and the forthcoming AI Act and regulations around the European Health Data Space.